Fig. 2From: 3-O-Methyldopa inhibits astrocyte-mediated dopaminergic neuroprotective effects of l-DOPAGSH levels in striatal astrocytes (a, b) or in their GCM (c) after the treatment with 3-OMD (10 or 100 µM) alone (a) or methyl-l-DOPA (25 or 100 µM) and 3-OMD (10 or 100 µM) (b, c) for 24 h. Data are mean ± SEM (n = 6). *p < 0.05, **p < 0.01, ***p < 0.001 versus control vehicle-treated, ##p < 0.01 versus methyl-l-DOPA-treated groupBack to article page